Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.

EBioMedicine - 1 Dec 2019

Schneeweiss-Gleixner Mathias, Byrgazov Konstantin, Stefanzl Gabriele, Berger Daniela, Eisenwort Gregor, Lucini Chantal Blanche, Herndlhofer Susanne, Preuner Sandra, Obrova Klara, Pusic Petra, Witzeneder Nadine, Greiner Georg, Hoermann Gregor, Sperr Wolfgang R, Lion Thomas, Deininger Michael, Valent Peter, Gleixner Karoline V

Abstract excerpt

PURPOSE: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1T315I-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1T315I-mutated CML remains a clinical challenge. Hydroxyurea (HU) has been used for cytoreduction in CML for decades. We found that HU suppresses or even eliminates BCR-ABL1T315I+ sub-clones in heavily pretreated CML...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase 6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Fusion Proteins, bcr-abl

Share to Hydroxyurea

Share to Imidazoles

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Pyridazines

Source

Open in PubMed Open full text

Identifiers

PMID: 31761618
DOI: 10.1016/j.ebiom.2019.11.004
PMCID: PMC6921367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.PMID 31761618Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Semantic proximity Read ↗

Targeting cell cycle regulators in hematologic malignanciesSemantic proximity Read ↗

Advances in Targeting BCR-ABLT315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.Semantic proximity Read ↗

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.Semantic proximity Read ↗

The Antineoplastic Role of STAT5 Inhibition in BCRABL1-Positive Cells Exposed to Pimozide Alone and in Combination with Dasatinib and PonatinibSemantic proximity Read ↗

Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity Read ↗

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.Semantic proximity Read ↗

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy InhibitionSemantic proximity Read ↗

Resistant mutations in CML and Ph+ALL &ndash; role of ponatinibSemantic proximity Read ↗

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.Semantic proximity Read ↗

Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.